CN112656887B - Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof - Google Patents
Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof Download PDFInfo
- Publication number
- CN112656887B CN112656887B CN202110115194.XA CN202110115194A CN112656887B CN 112656887 B CN112656887 B CN 112656887B CN 202110115194 A CN202110115194 A CN 202110115194A CN 112656887 B CN112656887 B CN 112656887B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- preparation
- inflammatory
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 230000006870 function Effects 0.000 title claims abstract description 28
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 20
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 29
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 32
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 29
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 29
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 29
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 29
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 29
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 29
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 29
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 29
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 29
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 29
- 241000606265 Valeriana jatamansi Species 0.000 claims abstract description 29
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 28
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 28
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 28
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 28
- 235000004347 Perilla Nutrition 0.000 claims abstract description 27
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 244000124853 Perilla frutescens Species 0.000 claims abstract 3
- 244000294611 Punica granatum Species 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 16
- 238000010298 pulverizing process Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 37
- 230000003647 oxidation Effects 0.000 abstract description 23
- 238000007254 oxidation reaction Methods 0.000 abstract description 23
- 206010061218 Inflammation Diseases 0.000 abstract description 21
- 230000004054 inflammatory process Effects 0.000 abstract description 21
- 206010012735 Diarrhoea Diseases 0.000 abstract description 18
- 230000036039 immunity Effects 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 230000012010 growth Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000005728 strengthening Methods 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 238000003306 harvesting Methods 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 description 44
- 241000219991 Lythraceae Species 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 241001092040 Crataegus Species 0.000 description 26
- 241000229722 Perilla <angiosperm> Species 0.000 description 24
- 239000000463 material Substances 0.000 description 18
- 238000012449 Kunming mouse Methods 0.000 description 17
- 230000008901 benefit Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 14
- 229940118019 malondialdehyde Drugs 0.000 description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 210000001541 thymus gland Anatomy 0.000 description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000004879 dioscorea Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000192710 Microcystis aeruginosa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to the technical field of anti-inflammatory and antioxidant traditional Chinese medicine compositions, aiming at solving the defects that the anti-inflammatory and antioxidant capabilities of cultured animals are deteriorated and the immunity is reduced because the existing antibiotics cannot be added into feed, and the traditional Chinese medicine composition comprises the following components in percentage by weight: 1-80% of Chinese yam, 1-80% of pomegranate peel, 1-20% of dried orange peel, 1-20% of valeriana jatamansi jones, 5-10% of hawthorn, 1-5% of perilla leaf, and 6 medicines of Chinese yam, pomegranate peel, dried orange peel, valeriana jatamansi jones, hawthorn and perilla leaf are used together, so that the effects of treating both principal and secondary aspects of disease, eliminating pathogenic factors, not forgetting and strengthening body resistance, combining sour harvest and pungent movement, and playing a role in resisting diarrhea, resisting inflammation and oxidation, promoting growth and improving immunity are achieved.
Description
Technical Field
The invention discloses a traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, a preparation and a preparation method thereof, belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to the technical field of anti-inflammatory and antioxidant traditional Chinese medicine compositions.
Background
The hormone is a medicine with wide application and remarkable treatment effect. Hormonal drugs can be classified into: glucocorticoids, adrenocorticoids, norepinephrine, progestins, estrogens, androgens, and the like.
Glucocorticoid (GC) is an extremely important regulatory molecule in the body, plays an important role in regulating development, growth, metabolism, immune function and the like of the body, is the most important regulatory hormone for stress response of the body, and is also the most widely and effectively anti-inflammatory and immunosuppressant in clinic. The clinically common glucocorticoid medicaments comprise prednisone, methylprednisolone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone and the like. Has antiinflammatory, antitoxic, antiallergic, antishock, nonspecific immunity inhibiting and antipyretic effects, and can prevent and stop immune inflammatory reaction and pathological immune reaction, and is almost effective for allergic diseases of any type.
The antibiotic is added into the feed, so that the disease of the livestock and poultry can be prevented, the metabolism of the livestock and poultry can be improved, the growth of the livestock and poultry can be promoted, and the survival rate and the feed conversion rate can be improved. In addition, the anti-inflammatory and antioxidant capacity of the cultured animals can be improved, and the immunity is improved. The department of agriculture issues a notification about national animal source bacteria resistance inhibition action plan (2017 + 2020), and after a few days, the department of agriculture publishes a notification about animal antibacterial use reduction action test point development work in offices in the department of agriculture countryside, and organizes and formulates an animal antibacterial use reduction action test point working scheme (2018 + 2021). Before 2020, the resistance is forbidden at the feed end, and the resistance reduction and resistance reduction at the breeding end are inevitable!
Disclosure of Invention
The invention aims to: provides a traditional Chinese medicine composition with anti-inflammatory and anti-oxidation functions, a preparation and a preparation method thereof, and aims to overcome the defects that the anti-inflammatory and anti-oxidation capabilities of cultured animals are deteriorated and the immunity is reduced because the existing antibiotics cannot be added into feed.
The technical scheme adopted by the invention is as follows:
the traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 1-80% of Chinese yam, 1-80% of pomegranate peel, 1-20% of dried orange peel, 1-20% of valeriana jatamansi, 5-10% of hawthorn and 1-5% of perilla leaf.
In the technical scheme of the application:
the yam is sweet and mild in nature and taste, is not greasy and dry, and has the effects of tonifying spleen and qi, tonifying spleen qi and tonifying spleen yin; the yam can not only strengthen the spleen and replenish qi, but also alleviate diarrhea with slight astringency, and is good at treating the symptoms of spleen deficiency loose stool or diarrhea; contains amylase, polyphenol oxidase, etc., and is beneficial to the digestion and absorption function of spleen and stomach; the copper ions, connective tissues and calcium in the Chinese yam are greatly helpful for livestock and poultry, have the function of enhancing immunity, also contain rich DHEA, are derivatives of cyclopentane polyhydrophenanthrene, and have the functions of resisting aging, enhancing immunity, enhancing the capability of resisting diseases and accelerating the repair of damaged tissues;
the dried pericarp of pomegranate of Punicaceae is sour and astringent, warm in nature, and has effects of large intestine meridian, relieving diarrhea with astringents, stopping bleeding, expelling parasites, resisting bacteria, fungi and virus, improving immunity, and resisting oxidation.
The dried orange peel is also called as orange peel, has the effects of regulating qi, strengthening spleen, eliminating dampness, harmonizing stomach, stimulating appetite, strengthening spleen, promoting qi circulation, stopping diarrhea and improving bile secretion capacity, and the volatile oil in the dried orange peel has the effects of eliminating phlegm, relieving asthma and expanding bronchus, can effectively stimulate the smooth muscle of gastrointestinal tract and is beneficial to promoting the secretion of digestive juice, so that the effects of eliminating intestinal tract pneumatosis and enhancing appetite can be achieved, and the effects of aromatic stomach strengthening and bitter taste discharge of the dried orange peel can be exerted; the dried orange peel contains flavonoid compounds, has strong effects of inhibiting the automatic oxidation of animal oil, removing hydroxyl free radicals (OH) and the like, can inhibit the lipid peroxidation of animal brain, heart and liver tissues, can also enhance the relative activity of SOD enzyme, and also has the effects of inhibiting oxidation and protecting liver;
the valeriana jatamansi jones have the effects of regulating qi to alleviate pain, helping digestion to stop diarrhea, dispelling wind and removing dampness, and tranquilizing and allaying excitement, and are used for treating abdominal distension and pain, indigestion, diarrhea and dysentery, rheumatism and arthralgia and the like.
The hawthorn is sour, sweet and slightly warm in nature and taste, has the effects of promoting digestion, invigorating stomach, promoting blood circulation and promoting qi circulation, can enter spleen and stomach to eliminate food retention and stagnation, disperse blood, can also treat water dysentery, not only helps pomegranate rind to stop diarrhea to treat the primary syndrome, but also helps to eliminate food retention and strengthen spleen and stomach to promote growth; the lipase is contained, so that the fat digestion can be promoted, the secretion of gastric digestive enzyme can be increased, and the digestion can be promoted; the hawthorn water extract has the function of removing O2Free radical, lipid peroxidation inhibition, antioxidation, immunity enhancement, antibacterial and analgesic effects;
folium Perillae, pungent and fragrant, and has effects of activating qi-flowing, activating spleen, stimulating appetite, increasing aroma, inhibiting odor, treating affection of exogenous wind-cold, and stagnation of qi due to dampness of spleen and stomach, contains volatile oil, flavone, phenolic acid, anthocyanin, polysaccharide, triterpene, and steroid, and has multiple biological activities such as antiinflammatory, antioxidant, antibacterial, antidepressant, antitumor, and tranquilizing;
the yam and the pomegranate rind are used for relieving diarrhea with astringents, mutual reinforcement and synergy; the Chinese yam is used as monarch drug for strengthening body resistance and tonifying deficiency, and the pomegranate bark can eliminate pathogenic factors and supplement each other; the dried orange peel and the valeriana jatamansi jones are used for assisting in regulating qi, strengthening spleen, eliminating dampness, harmonizing stomach, tranquilizing and promoting growth, have anti-inflammatory and antioxidant effects and are ministerial drugs; the hawthorn and the perilla leaf can help digestion and stop diarrhea, or eliminate dampness and regulate the middle warmer, or deodorize and enhance flavor, and can be used as assistant and guide products together, thereby conforming to the compatibility principle of 'assistant, minister, assistant and guide'. The traditional Chinese medicine composition has the effects of treating both manifestation and root cause of disease, eliminating pathogenic factors, strengthening body resistance, combining sour harvest and pungent flavor, and playing the effects of resisting diarrhea, resisting inflammation and oxidation, promoting growth and improving immunity.
The traditional Chinese medicine composition disclosed by the application starts from controlling diarrhea, protects the gastrointestinal mucosa damaged by the diarrhea and promotes repair, removes intercellular oxygen radicals, controls the extravasation of interstitial fluid, and rebalances the intracellular and extracellular environments.
In the diarrhea state, the condition that only the environment in the digestive tract is balanced is not enough to eliminate the symptoms, the process that the body automatically restores to be in the normal state is a long process, and the disease condition is repeated possibly. From the long-term effect, the organism in the state of vigorous immunity is not easily influenced by the external environment, from the cultivation aspect, the cultivation environment, such as the change of temperature, humidity, infectious diseases and the like, is not easily influenced by the growth of cultivated animals, the valeriana jatamansi jones and the perilla leaves have various efficacies of inflammation resistance, oxidation resistance, virus resistance, bacteria resistance and the like, and are combined with the dried orange peel and the hawthorn which have the function of promoting digestion and absorption, so that the function of promoting growth is finally achieved.
Preferably, the traditional Chinese medicine composition comprises the following components in percentage by weight: 1-79% of Chinese yam, 1-79% of pomegranate peel, 5-10% of dried orange peel, 5-10% of valeriana jatamansi, 5-7% of hawthorn and 1-5% of perilla leaf.
Preferably, the traditional Chinese medicine composition comprises the following components in percentage by weight: 10-70% of Chinese yam, 10-70% of pomegranate bark, 5-12% of dried orange peel, 5-12% of valeriana jatamansi, 5-8% of hawthorn and 1-5% of perilla leaf.
Preferably, the traditional Chinese medicine composition comprises the following components in percentage by weight: 20-60% of Chinese yam, 20-60% of pomegranate peel, 5-15% of dried orange peel, 5-15% of valeriana jatamansi, 5-9% of hawthorn and 1-5% of perilla leaf.
Preferably, the traditional Chinese medicine composition comprises the following components in percentage by weight: 30-45% of Chinese yam, 30-45% of pomegranate peel, 5-17% of dried orange peel, 5-17% of valeriana jatamansi, 5-10% of hawthorn and 1-5% of perilla leaf.
Preferably, the traditional Chinese medicine composition comprises the following components in percentage by weight: 35% of Chinese yam, 35% of pomegranate peel, 10% of dried orange peel, 9.5% of valeriana jatamansi, 7.5% of hawthorn and 3% of perilla leaf.
A Chinese medicinal composition with antiinflammatory and antioxidant effects is provided.
The preparation can be any one of tablets, granules, powder and pills.
A preparation method of the preparation comprises the steps of crushing the Chinese yam, the pomegranate rind, the dried orange peel, the valeriana jatamansi jones, the hawthorn and the perilla leaf according to the weight percentage, and preparing the preparation according to a conventional method.
In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that:
1. in the invention, the Chinese yam and the pomegranate rind are used for relieving diarrhea with astringents, and mutual reinforcement and synergy are realized; the Chinese yam is used as monarch drug for strengthening body resistance and tonifying deficiency, and the pomegranate bark can eliminate pathogenic factors and supplement each other; the dried orange peel and the valeriana jatamansi jones are used for assisting in regulating qi, strengthening spleen, eliminating dampness, harmonizing stomach, tranquilizing and promoting growth, have anti-inflammatory and antioxidant effects and are ministerial drugs; the hawthorn and the perilla leaf can help digestion and stop diarrhea, or eliminate dampness and regulate the middle warmer, or deodorize and enhance flavor, and can be used as assistant and guide products to meet the compatibility principle of 'assistant, minister, assistant and guide';
2. according to the invention, 6 medicines of Chinese yam, pomegranate rind, dried orange peel, valeriana jatamansi jones, hawthorn and perilla leaf are used together, so that both the principal and secondary aspects of the disease are considered, the pathogenic factors are eliminated, the body resistance is not forgotten, the sour harvest and the pungent flavor are combined, and the diarrhea resistance, the anti-inflammatory and the anti-oxidation effects are achieved together, the growth is promoted, and the immunity is improved;
3. according to the invention, the traditional Chinese medicine composition can effectively reduce the inflammation level of Kunming mice, has a certain antioxidation effect and has a certain dose-effect relationship.
Drawings
FIG. 1 is the effect of TK of the invention on body weight of Kunming mice;
FIG. 2 is a graph of the effect of TK of the invention on Kunming mouse spleen index;
FIG. 3 is the effect of TK of the invention on Kunming mouse thymus index;
FIG. 4 is the effect of TK of the invention on IL-1 β in serum of Kunming mice;
FIG. 5 is the effect of TK of the invention on IL-6 in serum of Kunming mice;
FIG. 6 is the effect of TK of the invention on IL-6 in the spleen of Kunming mice;
FIG. 7 is the effect of TK of the invention on TNF- α in serum of Kunming mice;
FIG. 8 is a graph of the effect of TK of the invention on TNF- α in the spleen of Kunming mice;
FIG. 9 is the effect of TK of the invention on SOD in serum of Kunming mice;
FIG. 10 is the effect of TK of the invention on MDA in Kunming mouse serum;
FIG. 11 is the effect of TK of the invention on MDA in the spleen of Kunming mice.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 79% of Chinese yam, 1% of pomegranate peel, 6.5% of dried orange peel, 6% of valeriana jatamansi, 5.5% of hawthorn and 2% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder. The yam and the pomegranate rind jointly form the main components of the scheme, the two components are matched to realize the main effects, and the proportion mainly considers the balance relationship between the effect and the material cost.
Example 2
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 1% of Chinese yam, 79% of pomegranate peel, 6.5% of dried orange peel, 6% of valeriana jatamansi, 5.5% of hawthorn and 2% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder. The yam and the pomegranate rind jointly form the main components of the scheme, the two components are matched to realize the main effects, and the proportion mainly considers the balance relationship between the effect and the material cost.
Example 3
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 70% of Chinese yam, 10% of pomegranate peel, 6.5% of dried orange peel, 6.5% of valeriana jatamansi, 5% of hawthorn and 2% of perilla leaf. The preparation method comprises pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 4
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 10% of Chinese yam, 70% of pomegranate peel, 6.5% of dried orange peel, 6.5% of valeriana jatamansi, 5% of hawthorn and 2% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 5
The traditional Chinese medicine composition with the functions of inflammation resistance and oxidation resistance comprises the following components in percentage by weight: 60% of Chinese yam, 20% of pomegranate peel, 6% of dried orange peel, 6% of valeriana jatamansi, 5.5% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 6
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 20% of Chinese yam, 60% of pomegranate peel, 6% of dried orange peel, 6% of valeriana jatamansi, 5.5% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 7
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 45% of Chinese yam, 30% of pomegranate peel, 8% of dried orange peel, 7.5% of valeriana jatamansi, 7% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 8
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 30% of Chinese yam, 45% of pomegranate peel, 8% of dried orange peel, 7.5% of valeriana jatamansi, 7% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 9
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 38% of Chinese yam, 38% of pomegranate peel, 8% of dried orange peel, 8% of valeriana jatamansi, 6% of hawthorn and 2% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 10
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 36% of Chinese yam, 36% of pomegranate rind, 9.5% of dried orange peel, 8.5% of valeriana jatamansi jones, 7.5% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 11
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 35% of Chinese yam, 35% of pomegranate peel, 10% of dried orange peel, 9.5% of valeriana jatamansi, 8% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 12
The traditional Chinese medicine composition with the functions of resisting inflammation and resisting oxidation comprises the following components in percentage by weight: 35% of Chinese yam, 34% of pomegranate peel, 10% of dried orange peel, 9.5% of valeriana jatamansi, 9% of hawthorn and 2.5% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
Example 13
The traditional Chinese medicine composition with the functions of inflammation resistance and oxidation resistance comprises the following components in percentage by weight: 34% of Chinese yam, 34% of pomegranate peel, 10% of dried orange peel, 10% of valeriana jatamansi, 9% of hawthorn and 3% of perilla leaf. The preparation method comprises the following steps: pulverizing the above Chinese medicinal materials in percentage by weight, mixing, and making into powder.
The tablets, granules or pills can also be prepared by adopting medically acceptable auxiliary materials according to a conventional method in the examples 1 to 13 of the application.
Test examples
The anti-inflammatory and antioxidant effects of the traditional Chinese medicine composition powder prepared in example 5, hereinafter referred to as TK drug, on Kunming mice were studied:
materials and reagents
Animals including SPF-level Kunming mouse, female mouse, 4-6 weeks old, body weight 16 + -2 g, 7 groups including 6 mice and 42 mice;
LPS, TK, 0.3% CMC, and dexamethasone;
the kit comprises: ELISA detection kits for IL-6, IL-1 beta, TNF-alpha and the like (American Saimei Fei); MDA, SOD biochemical detection kit (built by Nanjing); peroxidase antibody (U.S. CST); quantitative PCR kit and cytokine primers (Shanghai's worker) such as IL-6, IL-1 beta, TNF-alpha and the like.
Second, method
Mice were randomly divided by weight:
normal control group (NC): irrigating equal amount of CMC for 1 time/d;
inflammation model group (LPS): irrigating equal amount of CMC for 1 time/d;
dexamethasone control group (DXM): irrigating equal amount of CMC for 1 time/d;
TK low dose group (TK-L): irrigating 0.2g/kg TK for 1 time/d;
TK middle dose group (TK-M): irrigating 0.8g/kg TK for 1 time/d;
TK high dose group (TK-H): drench 3.2g/kg TK, 1 time/d.
The equivalent CMC is infused, namely the CMC is correspondingly given to other control groups with the same volume according to the dose of the injected TK drug, the weight average value of the experimental mouse does not exceed 25g, and the infusion dose setting standard is that the administration volume of each 10g weight mouse is 0.2ml, so that the administration volume of the experiment is 0.2ml/10 g/25 g-0.5 ml/mouse.
Dosing and modeling:
each group of experimental animals was administered 1 time per day at a dose and manner of 6d continuously. All animals were fasted without water deprivation after dosing on day 6. Except for the normal control group, LPS was intraperitoneally injected at a dose of 30mg/kg once after the last administration of 30min on day 7 (the positive control group was intraperitoneally injected with dexamethasone injection (10mg/kg) on day 7) in each of the other groups for establishing a mouse acute inflammation model. Immediately performing orbital bleeding after 6h, standing at 4 ℃ for at least 30min, centrifuging at 3000r/min for 10min, collecting supernatant, subpackaging, and storing in a refrigerator at-80 ℃ for later use. The collected animal is killed by dislocation of cervical vertebra, spleen, thymus, liver and pancreas of the mouse are dissected and taken, weighed and respectively preserved in a refrigerator with the temperature of 80 ℃ below zero and 4% paraformaldehyde solution for fixation for later use.
Research shows that the acute inflammation model in the body of the mouse can be successfully established by injecting 10-15mg/kg LPS into the abdominal cavity, but the previous experimental results of the inventor show that the inflammation model is not successfully established by injecting the LPS into the abdominal cavity, so that through continuous research and research of a subject group, the LPS dose is finally fixed at 30mg/kg, and meanwhile, the modeling success rate and the survival rate of the mouse are considered.
Third, detecting the index
Weighing the body weight 1 time every 3 days;
organ index: spleen, liver, pancreas and thymus, for example, spleen index determination, the body mass of a dissected mouse is weighed, the spleen of the mouse is taken, and the spleen index is determined. Spleen index formula spleen index equals spleen mass (mg)/body mass (g), and other indices were calculated in the same manner. (spleen and thymus are important immune organs, spleen index and thymus index are significant in prompting the strong and weak state of immunity; if the spleen index of an experimental group is higher than that of a control group, the immunity of the organism is prompted to be enhanced; on the contrary, some cytotoxic drugs such as cyclophosphamide have very strong immunosuppressive action and can comprehensively reduce the immune function of the organism, so that the index is reduced, and the index change of an immunomodulator is not obvious.)
Detecting the expression levels of inflammatory factors (kit) IL-6, IL-1 beta, TNF-alpha and the like in serum by an ELISA method;
detecting the expression of inflammatory factors IL-6, IL-1 beta and TNF-alpha mRNA in tissues by a PCR method;
detecting related indexes of antioxidation by a biochemical method (kit): MDA, SOD;
examples of pathological tissue structure changes of organs (spleen, liver, pancreas and thymus are selected according to actual anatomical conditions for HE staining): observing the change of the mouse liver tissue structure (HE staining), dissecting the mouse liver tissue, fixing by 4% paraformaldehyde solution, taking materials conventionally, dehydrating, dipping in wax, embedding, flaking (4 μm thick), dewaxing, hydrating, hematoxylin-eosin staining, and observing the structural change of the mouse liver tissue after scanning by a panoramic scanner;
immunohistochemical detection of peroxidase (determined according to 5 and 6 experimental results) is carried out by subjecting prepared paraffin sections of liver to deparaffinization and water bloom, thermoantigen repair and endogenous peroxidase inactivation by 3% H2O2, blocking nonspecific sites with goat serum, adding primary antibody, incubating overnight in a refrigerator at 4 ℃, incubating secondary antibody, staining with DAB and hematoxylin, dehydrating, permeabilizing, sealing with neutral gum, microscopic examination and Image analysis by Image-Proplus.6.0 software.
Fourth, data statistics
Statistical differences of the measurement indexes of each group are analyzed by adopting one-way analysis of variance (ANOVA), all statistical analysis is completed under SPSS Statistics 18.0 software, and p is less than 0.05 and less than 0.01, which indicates that the differences have statistical significance.
Fifth, test results
1. Body weight
The Body weight of each group of mice is recorded in Table 1, FIG. 1 (Body weight (g) in FIG. 1 is Body weight (g)). As can be seen from the data in the graph, the weight values of all groups have no statistical difference (p is more than 0.05), and the TK medicament has low toxicity and no obvious influence on the weight of the mice.
The body weight of each group of mice is recorded in table 1, fig. 1. As can be seen from the data in the graph, the weight values of all groups have no statistical difference (p is more than 0.05), and the TK medicament has low toxicity and no obvious influence on the weight of the mice.
TABLE 1 Effect of TK on Kunming mouse weight (` x. + -. s, g)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
2. Index of visceral organs
2.1 spleen index
The Spleen index results are shown in Table 2, and FIG. 2(Spleen index (mg/g) is the Spleen index (mg/g)), in FIG. 2: compared with the normal control group, the composition has the advantages that,##p<0.01, p compared to model control group<0.05,**p<0.01. Spleen index was significantly increased in the model group compared to the normal group (p)<0.01), the spleen swelling degree of the model group is far higher than that of the normal group. Compared with the model group, the spleen swelling degree of the dexamethasone group, the TK-M group and the TK-H group is obviously reduced compared with the model group (p)<0.05 or p<0.01)。
TABLE 2 influence of TK on Kunming mouse spleen index (` x. + -. s, g)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
2.2. Index of thymus
The Thymus index results are shown in Table 3, FIG. 3(Thymus index (mg/g)) in FIG. 3: compared with the normal control group, the composition has the advantages that,##p<0.01, p compared to model control group<0.05,**p<0.01. Compared with the model group, the thymus swelling degree of the dexamethasone group, the TK-M group and the TK-H group is obviously reduced compared with the model group (p)<0.05 or p<0.01)。
TABLE 3 influence of TK on Kunming mouse thymus index (` x. + -. s, g)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
3. Inflammatory factors
3.1IL-1β
The results of ELISA detection of IL-1. beta. in mouse serum are shown in Table 4 and FIG. 4, and in FIG. 4, the following are noted: compared with the normal control group, the composition has the advantages that,##p<0.01, p compared to model control group<0.05,**p<0.01, the IL-1 beta level in the model group is far higher than that in the normal group (p < 0.01), other administration groups can effectively reduce the IL-1 beta level (p < 0.01), and each TK group shows good dose dependence.
TABLE 4 ELISA detection of IL-1. beta. levels in mouse serum (` x. + -. s, pg/ml)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
3.2IL-6
The results of ELISA detection of IL-6 in mouse serum are shown in Table 5 and FIG. 5,in fig. 5, note: compared with the normal control group, the composition has the advantages that,##p<0.01, p compared to model control group<0.05,**p<0.01, the IL-6 level in the model group is far higher than that in the normal group (p is less than 0.01), and the TK-H group can effectively reduce the IL-6 level (p is less than 0.01).
TABLE 5 ELISA for serum IL-6 levels (` x. + -. s, pg/ml) in mice
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<The results of 0.01ELISA assay for mouse spleen IL-6 are shown in Table 6 and FIG. 6, in FIG. 6, note: compared with the normal control group, the composition has the advantages that,##p<0.01, p compared to model control group<0.05,**p<0.01, the IL-6 level in the model group is far higher than that in the normal group (p < 0.01), other administration groups can effectively reduce the IL-6 level (p < 0.01), and each TK group shows good dose dependence.
TABLE 6 detection of mouse spleen IL-6 levels by ELISA (` x. + -. s, pg/ml)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
3.3TNF-α
The results of the ELISA assay for mouse serum TNF- α are shown in Table 7 and FIG. 7, in FIG. 7, note: compared with the normal control group, the composition has the advantages that,##p<0.01, p compared to model control group<0.05,**p<0.01, TNF- α levels in the model group were much higher than in the normal group (p < 0.01). Compared with the model group, the dexamethasone group, the TK-M group and the TK-H group can effectively reduce the TNF-alpha level (p is less than 0.01), and each TK group has good dose dependence.
TABLE 7 ELISA detection of mouse serum TNF-. alpha.levels (` x. + -. s, pg/ml)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
The results of ELISA assay of mouse spleen TNF-. alpha.are shown in Table 8 and FIG. 8, in FIG. 8, compared with the normal control group,#p<0.05,##p<0.01; p compared to model control group<0.05,**p<0.01, TNF- α levels in the model group were much higher than in the normal group (p < 0.01). Compared with the model group, the dexamethasone group and the TK-H group can effectively reduce the level of TNF-alpha (p is less than 0.01).
TABLE 8 ELISA detection of mouse spleen TNF-. alpha.levels (` x. + -. s, pg/ml)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
4. Index of oxidation
4.1SOD
Superoxide dismutase (SOD) has the function of catalyzing superoxide anion free radicals to form hydrogen peroxide, and further decomposing the hydrogen peroxide into water and oxygen, so that the organism is protected from being damaged by oxidative stress. Therefore, the high and low levels of SOD activity directly reflect the body's ability to scavenge oxygen radicals.
The results of the microplate assay for detecting SOD in mouse serum are shown in Table 9 and FIG. 9, in FIG. 9, compared with the normal control group,#p<0.05,##p<0.01; p compared to model control group<0.05,**p<0.01, the SOD level in the model group is far lower than that in the normal group (p < 0.05). Compared with the model group, the TK-M and the TK-H groups can effectively increase SOD levels (p is less than 0.05), and each group of the TKExhibit good dose-dependence.
TABLE 9 microplate method for detecting mouse serum SOD activity level (` x. + -. s, U/ml)
Note: compared with the normal control group, the compound preparation,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
4.2MDA
MDA (malondialdehyde) is one of lipid peroxide products, oxidation products such as lipofuscin and the like are further generated in a body through a series of reactions such as protein crosslinking and the like and are accumulated in body cells, the normal structure and function of the body cell membrane are damaged, the burden of the body tissues is increased, finally, the body tissue cells cannot maintain the normal metabolism of the cells and are aged and dead, and the content of the oxidation products can indirectly reflect the degree of lipid peroxidation in the body and the severity of the body cells under the attack of free radicals.
The results of MDA detection in mouse serum by the TBA method are shown in table 10 and fig. 10, and in fig. 10, compared with the normal control group,#p<0.05,##p<0.01; p compared to model control group<0.05,**p<0.01, the MDA level in the model group is much higher than that in the normal group (p < 0.05). Compared with the model group, dexamethasone, TK-M and TK-H can effectively reduce MDA level (p is less than 0.01), and each group of TK has good dose dependence.
TABLE 10 detection of mouse serum MDA Activity level by TBA method (` x. + -. s, U/ml)
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
The results of MDA detection in mouse spleen by TBA method are shown in Table 11 and FIG. 11, in FIG. 11, compared with the normal control group,#p<0.05,##p<0.01; p compared to model control group<0.05,**p<0.01, MDA level in the model group is much higher than that in the normal group (p < 0.01). Each treatment group was effective in reducing MDA levels (p < 0.05) compared to the model group.
TABLE 11 TBA assay for spleen MDA viability levels (` x. + -. s, U/ml) in mice
Note: compared with the normal control group, the composition has the advantages that,#p<0.05,##p<0.01, p compared to model control group<0.05,**p<0.01
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (4)
1. A traditional Chinese medicine composition with anti-inflammatory and antioxidant functions is characterized in that: the traditional Chinese medicine composition comprises the following components in percentage by weight: 60% of Chinese yam, 20% of pomegranate peel, 6% of dried orange peel, 6% of valeriana jatamansi, 5.5% of hawthorn and 2.5% of perilla leaf.
2. A preparation of the anti-inflammatory and antioxidant Chinese medicinal composition of claim 1.
3. The formulation of claim 2, wherein: the preparation can be any one of tablets, granules, powder and pills.
4. A method of preparing the formulation of claim 2, wherein: pulverizing rhizoma Dioscoreae, pericarpium Granati, pericarpium Citri Tangerinae, Valeriana jatamansi jones, fructus crataegi and folium Perillae by the above weight percentage, and making into preparation by conventional method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110115194.XA CN112656887B (en) | 2021-01-27 | 2021-01-27 | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110115194.XA CN112656887B (en) | 2021-01-27 | 2021-01-27 | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112656887A CN112656887A (en) | 2021-04-16 |
CN112656887B true CN112656887B (en) | 2022-05-06 |
Family
ID=75414807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110115194.XA Active CN112656887B (en) | 2021-01-27 | 2021-01-27 | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112656887B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102908491A (en) * | 2012-11-15 | 2013-02-06 | 郑军辉 | Chinese medicinal powder for treating chronic diarrhea and preparation method thereof |
CN103223085A (en) * | 2013-04-08 | 2013-07-31 | 张宗升 | Chinese medicinal extract |
CN105770051A (en) * | 2014-12-26 | 2016-07-20 | 北京大北农动物保健科技有限责任公司 | Pharmaceutical composition for veterinary use, feed additive, feed and application thereof |
CN105395951A (en) * | 2015-12-17 | 2016-03-16 | 西南民族大学 | Natural medicine formula used for treating calf diarrhea, and preparation method thereof |
-
2021
- 2021-01-27 CN CN202110115194.XA patent/CN112656887B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN112656887A (en) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2124972A2 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
KR20080079743A (en) | Method of manufacturing fermented products using wild grasses having a therapeutic effect on atopic dermatitis | |
KR101447231B1 (en) | A manufacturing method of overhang solution pellet and overhang solution pellet munufactured by the same | |
Yampolsky et al. | Sea buckthorn (lat. Hippophaë) | |
JP2001342142A (en) | Composition for preventing and curing urologic disease | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
JP2000191542A (en) | Preventive/therapeutic agent for osteoporosis | |
WO2021213232A1 (en) | Application of traditional chinese medicine composition in preparing drug for treating or preventing hyperlipidemia | |
KR20240119051A (en) | Obesity prevention and treatment composition containing mulberry leaf and aronia complex | |
CN112656887B (en) | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof | |
CN101932332A (en) | Application of Labisia pumila extract to reduce the risk of cardiovascular disease | |
CN117770442A (en) | Camellia oil-based liver protection composition and application thereof | |
WO2016111477A1 (en) | Cosmetic composition for alleviation or improvement of sebum secretion stimulated by stress, comprising, as active ingredient, extract of carthamus tinctorious l. seed, or mixed extract of carthamus tinctorious l. seed and areca catechu l. seed | |
EP2680924B1 (en) | A novel herbal composition for the treatment of kidney stone and other urinary tract disorders | |
CN109954052A (en) | A kind of composition with antioxidant activity | |
CN106359659B (en) | A compound nutrient blending oil with ulcer repairing effect and its preparation method and application | |
KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
KR102507569B1 (en) | Preparation Method of Gynostemma pentaphyllum Leaves Extract and Gynostemma pentaphyllum Leaves Extract Using The Same | |
CN116942742B (en) | A uric acid-lowering traditional Chinese medicine composition and its preparation method | |
CN111728985B (en) | A composition containing oviductus Ranae as main ingredient and its application | |
KR20090081707A (en) | Compositions That Control Symptoms of Irritable Bowel Syndrome | |
KR102588877B1 (en) | Injection liquid composition for localized lipolysis and Administration method of the same | |
US10548936B2 (en) | Method for reducing weight | |
KR102113431B1 (en) | Anti-inflammatory composition containing medicinal herbs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |